U.S. market Closed. Opens in 1 day 50 minutes

ENTX | Entera Bio Ltd. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for ENTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -8.86 -15.27
PEG Ratio (TTM) -0.14 -4.35
P/S Ratio (TTM) 17.37 45.97
P/B Ratio (TTM) 12.60 28.96
P/FCF Ratio (TTM) -10.15 -2.59
Price to 5YR AVG Earnings Ratio -4.05 -5.56
Price to 5YR AVG FCF Ratio -8.22 -12.33

Profitability (25%)

Company Industry
ROA (TTM) -118.56% -19.06%
ROE (TTM) -107.24% 15.70%
Net Profit Margin (TTM) -200.35% -813.88%
ROIC 5YR AVG 788.21% 3.12%

Growth (38%)

4QTR AVG 3YR AVG 5YR AVG
EPS 67.65% 27.91% 23.82%
Revenue -31.58% 19.43% -23.65%
Net Income -8.04% -6.47% 1.06%
Cash Flow -18.40% 1.71% 1.75%

Health (49%)

Company Industry
Current Ratio (TTM) 6.61 5.56
Quick Ratio (TTM) 6.61 5.34
D/E Ratio (TTM) N/A 0.95
Interest Coverage (TTM) -288.16 -6.44
Piotroski F-Score 2 5
Altman Z-Score 12.83 12.45
LTL to 5YR AVG FCF -0.05 0.11
Shares Outstanding Growth 5YR AVG 31.43% 37.46%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙